Holen Sie sich die Stockscreener-App
6.53
0.91%
-0.08
Schlusskurs vom Vortag:
$6.61
Offen:
$6.405
24-Stunden-Volumen:
812.08K
Relative Volume:
0.39
Marktkapitalisierung:
$464.08M
Einnahmen:
$26.87M
Nettoeinkommen (Verlust:
$-137.06M
KGV:
-3.4219
EPS:
-1.9083
Netto-Cashflow:
$-125.25M
1W Leistung:
+143.49%
1M Leistung:
+141.70%
6M Leistung:
+304.32%
1J Leistung:
+432.52%
1-Tages-Spanne:
$6.38
$6.85
1-Wochen-Bereich:
$2.56
$6.95
52-Wochen-Spanne:
$1.13
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
6.5427 | 468.85M | 26.87M | -137.06M | -125.25M | -1.9083 |
VRTX
Vertex Pharmaceuticals Inc
|
440.00 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
801.91 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.90 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.41 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Yahoo Finance
Guggenheim Increases Zentalis Price Target, Sparking Investor Interest - timothysykes.com
Zentalis Stock Jumps as Guggenheim Lifts Price Target on Cancer Program Success - StocksToTrade
Zentalis Pharmaceuticals: Price Target Boost Sparks Speculative Momentum - timothysykes.com
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space? - Barchart.com
Jefferies raises Zentalis stock price target on ovarian cancer trial data - Investing.com Canada
What's behind the surge in Zentalis stock? - MSN
What's Behind The Surge In Zentalis Stock? - Benzinga
Today's Analyst Rating Update for ZNTL: Buy Rating Maintained wi - GuruFocus
H.C. Wainwright reiterates Zentalis stock rating on pivotal dose selection By Investing.com - Investing.com Canada
Azenosertib Shows Promising Results in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer: Zentalis Advances Registration-Intent Trials - Minichart
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - Bitget
Zentalis Advances Azenosertib Dose in DENALI Phase 2 - TipRanks
Zentalis Selects 400mg QD 5:2 Azenosertib Dose for Pivotal Ovarian Cancer Study - National Today
Zentalis selects 400mg QD 5:2 as pivotal azenosertib dose; DENALI topline due YE2026 - TradingView — Track All Markets
Azenosertib 400mg dose to anchor Zentalis (NASDAQ: ZNTL) late-stage ovarian cancer trials - Stock Titan
Ovarian cancer drug moves toward pivotal trials with 400mg dose - Stock Titan
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals PAO sells $7.8k in stock - Investing.com
Zentalis Pharmaceuticals announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Two new Zentalis hires get stock options priced at $2.57 - Stock Titan
ZNTL PE Ratio & Valuation, Is ZNTL Overvalued - Intellectia AI
Here's What to Expect From West Pharmaceutical's Next Earnings Report - Barchart.com
Sentiment Review: Is Zentalis Pharmaceuticals Inc currently under institutional pressure2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Brokers Issue Forecasts for ZNTL FY2030 Earnings - MarketBeat
Guggenheim Reiterates Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wall Street Zen to "Sell" - MarketBeat
TD Cowen reiterates Zentalis Pharmaceuticals stock Buy rating By Investing.com - Investing.com Canada
TD Cowen reiterates Zentalis Pharmaceuticals stock Buy rating - Investing.com
Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reiterated at Guggenheim - MarketBeat
Oppenheimer reiterates Zentalis stock rating on ovarian cancer drug By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Zentalis stock rating, $10 target By Investing.com - Investing.com Canada
Can Zentalis Pharmaceuticals Inc expand its profit marginsWeekly Market Outlook & Real-Time Sentiment Analysis - baoquankhu1.vn
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Zentalis Pharmaceuticals 2025 Annual Report: Azenosertib Development, Strategic Restructuring, and Competitive Positioning - Minichart
Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zentalis (ZNTL) centers strategy on azenosertib for Cyclin E1-positive ovarian cancer - Stock Titan
Zentalis Pharmaceuticals 10-K: $0 Revenue, $(137.1)M Net Loss - TradingView
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results - MarketBeat
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - Bitget
Zentalis Pharmaceuticals (Nasdaq: ZNTL) cuts costs, extends cash runway into 2027 - Stock Titan
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Investment Recap: Can Zentalis Pharmaceuticals Inc expand its profit margins2026 Reactions & Weekly High Potential Alerts - baoquankhu1.vn
ZNTL SEC FilingsZentalis Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Intraday: Can Zentalis Pharmaceuticals Inc keep up with sector leaders2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Profit Recap: Does Zentalis Pharmaceuticals Inc have a sustainable dividendEarnings Beat & Consistent Income Trade Ideas - baoquankhu1.vn
Zentalis Pharmaceuticals Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zentalis Pharmaceuticals Inc-Aktie (ZNTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 09 '26 |
Sale |
2.39 |
335 |
802 |
33,332 |
| Vultaggio Vincent | PAO and PFO |
Feb 06 '26 |
Sale |
2.43 |
29,951 |
72,772 |
156,779 |
| Vultaggio Vincent | PAO and PFO |
Feb 10 '26 |
Sale |
2.42 |
6,894 |
16,699 |
146,506 |
| Vultaggio Vincent | PAO and PFO |
Feb 09 '26 |
Sale |
2.39 |
3,379 |
8,086 |
153,400 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 06 '26 |
Sale |
2.43 |
7,866 |
19,112 |
80,022 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 09 '26 |
Sale |
2.39 |
889 |
2,127 |
79,133 |
| Vultaggio Vincent | PAO and PFO |
Feb 02 '26 |
Sale |
2.55 |
2,540 |
6,477 |
187,286 |
| Vultaggio Vincent | PAO and PFO |
Feb 03 '26 |
Sale |
2.52 |
556 |
1,398 |
186,730 |
| WALTERS GROUP | 10% Owner |
Dec 31 '25 |
Buy |
1.20 |
6,459,973 |
7,751,968 |
13,509,973 |
| Matrix Capital Management Comp | 10% Owner |
Dec 15 '25 |
Sale |
1.33 |
7,500,000 |
9,975,000 |
6,459,973 |
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):